Skip to content

Scientific Technology News

About STN
Contact Us

Top-10
Instrument Industry Deals
Product Launches

U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)

June 9, 2022June 21, 2022 by /

Share This.....

Share on linkedin

Share on twitter

Share on facebook

Share on google

Related News:

FDA Approves NGS-Based Companion Diagnostic for EGFR…
Roche receives FDA approval for first companion…
Shimadzu, Providence Cancer Institute, and Japanese…
Bruker Announces First 1.2 GHz NMR Installation in…
Nairobi Water Project Tops Fan Vote in Xylem and…
FDA approves Roche’s Vabysmo, the first bispecific…

Category: Acad, Gov/Utilities, Clinical Research/Diagn. Tag: Roche

Post navigation

Previous PostEuropean Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

Next PostXylem to Highlight Resilient Digital Solutions for the Rapidly-Evolving Water Utilities Industry at AWWA ACE 2022

Get market data and industry analysis here. Request a complimentary copy.

Related News

FDA Approves NGS-Based Companion Diagnostic for EGFR… December 9, 2021
Roche receives FDA approval for first companion… October 4, 2022
Shimadzu, Providence Cancer Institute, and Japanese… December 19, 2022
Bruker Announces First 1.2 GHz NMR Installation in… December 19, 2023
Nairobi Water Project Tops Fan Vote in Xylem and… November 29, 2023
FDA approves Roche’s Vabysmo, the first bispecific… January 31, 2022
FDA approves Roche’s Vabysmo, the first bispecific… January 31, 2022
FDA approves Roche’s Evrysdi for use in babies under… May 31, 2022
FDA approves Roche’s Lunsumio, a first-in-class… December 23, 2022
FDA approves Roche’s Actemra for the treatment of… December 21, 2022

© 2024 Scientific Technology News